Daily Stock Analysis, CEMI, Chembio Diagnostics Inc, priceseries

Chembio Diagnostics Inc. Daily Stock Analysis
Stock Information
Open
4.43
Close
4.18
High
4.63
Low
4.15
Previous Close
4.28
Daily Price Gain
-0.10
YTD High
7.90
YTD High Date
May 17, 2019
YTD Low
3.95
YTD Low Date
Nov 14, 2019
YTD Price Change
-1.48
YTD Gain
-26.15%
52 Week High
7.90
52 Week High Date
May 17, 2019
52 Week Low
3.95
52 Week Low Date
Nov 14, 2019
52 Week Price Change
-1.80
52 Week Gain
-30.10%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 7. 2017
5.45
May 17. 2017
6.62
27 Trading Days
21.48%
Link
LONG
Dec 15. 2017
7.30
Jan 22. 2018
8.66
23 Trading Days
18.59%
Link
LONG
May 10. 2018
8.15
May 24. 2018
8.58
10 Trading Days
5.29%
Link
LONG
Jan 4. 2019
6.00
Feb 6. 2019
6.79
22 Trading Days
13.23%
Link
LONG
Apr 5. 2019
6.13
May 1. 2019
7.12
17 Trading Days
16.22%
Link
LONG
Sep 3. 2019
5.40
Sep 27. 2019
6.72
18 Trading Days
24.47%
Link
Company Information
Stock Symbol
CEMI
Exchange
NasdaqCM
Company URL
http://www.chembio.com
Company Phone
(631) 924-1135
CEO
John J. Sperzel
Headquarters
New York
Business Address
3661 HORSEBLOCK ROAD, MEDFORD, NY 11763
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
0001092662
About

Chembio Diagnostics, Inc. develops, manufactures, markets and licenses rapid point-of-care diagnostic tests that detect infectious diseases. It sells its products under its STAT PAK, SURE CHECK, DPP and SampleTainer trademarks. The company was founded on May 5, 2004 and is headquartered in Medford, NY.

Description

Chembio Diagnostics, Inc., together with its subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. It offers rapid tests for the detection of HIV and syphilis antibodies. The company's products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV 1/2 Assay Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a DPP HIV-Syphilis multiplex test for the detection of antibodies to HIV and syphilis; and a test for the detection of Hepatitis-C. Chembio Diagnostics, Inc. sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; and collaboration with an international diagnostics company to develop a POC diagnostic test for a specific type of cancer. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.